Lineage Cell Therapeutics, Inc. (LCTX)

Sentiment-Signal

17,6

Stark Bearisch

Composite Score (0–100)

Insider (25%)

23.4

1 Insider, 24K $ Volumen

Institutionell (22,5%)

Keine neuen Positionen

Aktivist (12,5%)

Kein 13D/13G

Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Kritische 8-K Meldungen

Datum	Meldung	Schwere	Filing	Auszug
02.07.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment
07.09.2023	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

Stammdaten

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Unternehmen & Branche

Name	Lineage Cell Therapeutics, Inc.
Ticker	LCTX
CIK	0000876343
Boerse	US
Sektor	Healthcare
Industrie	Biotechnology
SIC	2836 · Biological Products, (No Diagnostic Substances)

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	388,6 Mio. USD
Beta	1,80
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	14,556,000	-63,533,000	-0.28	112,584,000	44,549,000
2025-09-30	10-Q	3,681,000	-29,781,000	-0.13	89,639,000	22,040,000
2025-06-30	10-Q	2,765,000	-30,464,000	-0.13	90,799,000	48,385,000
2025-03-31	10-Q	1,502,000	-4,139,000	-0.02	111,753,000	79,028,000
2024-12-31	10-K	9,499,000	-18,609,000	-0.09	113,218,000	78,381,000
2024-09-30	10-Q	3,779,000	-3,034,000	-0.02	96,594,000	66,186,000
2024-06-30	10-Q	1,408,000	-5,760,000	-0.03	102,802,000	68,300,000
2024-03-31	10-Q	1,444,000	-6,542,000	-0.04	108,483,000	72,402,000
2023-12-31	10-K	2,088,000	-4,775,000	-0.03	101,019,000	63,419,000
2023-09-30	10-Q	1,246,000	-7,110,000	-0.04	106,153,000	68,117,000
2023-09-30	10-K	1,246,000	-7,110,000	-0.04
2023-06-30	10-K	3,225,000	-5,229,000	-0.03
2023-06-30	10-Q	3,225,000	-5,229,000	-0.03	111,688,000	72,667,000
2023-03-31	10-Q	2,386,000	-4,372,000	-0.03	113,205,000	70,450,000
2023-03-31	10-K	2,386,000	-4,372,000	-0.03
2022-12-31	10-K	1,915,000	-6,354,000	-0.03	123,664,000	73,339,000
2022-09-30	10-K	2,998,000	-6,069,000	-0.04
2022-09-30	10-Q	2,998,000	-6,069,000	-0.04	131,148,000	78,948,000
2022-06-30	10-Q	4,553,000	-6,763,000	-0.04	135,922,000	82,847,000
2022-06-30	10-K	4,553,000	-6,763,000	-0.04

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ	Trend
2026-03-12	Culley Brian M	Director, Officer, President and CEO	Open Market Purchase	15,000	1.63	24,375.00	+100,0%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.